VALANX Biotech secures ?3 million to advance LIV-1 ADC for metastatic triple-negative - HER2 Support Group Forums

		HER2 Support Group Forums > General Cancer News
VALANX Biotech secures ?3 million to advance LIV-1 ADC for metastatic triple-negative

General Cancer News Latest Breast Cancer News from Moreover Technologies

Reply

03-12-2026, 05:40 AM	#1
News Senior Member Join Date: Oct 2007 Posts: 19,921	VALANX Biotech secures ?3 million to advance LIV-1 ADC for metastatic triple-negative VALANX Biotech (VALANX), a biotech company developing a technology for site-selectable, site-specific protein conjugation, today announced it has secured ?3 million to advance its lead antibody-drug conjugate (ADC) program. More...

Reply

« Previous Thread | Next Thread »

Posting Rules
You may not post new threads You may not post replies You may not post attachments You may not edit your posts BB code is On Smilies are On [IMG] code is On HTML code is Off Forum Rules

All times are GMT -7. The time now is 11:34 AM.

free webpage hit counter